Risperidone Patent Expiration
Risperidone is used for treating various conditions such as depression, anxiety, and obsessive-compulsive disorder. It was first introduced by Janssen Pharmaceuticals Inc
Risperidone Patents
Given below is the list of patents protecting Risperidone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Perseris Kit | US10010612 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
| Perseris Kit | US10058554 | Sustained release small molecule drug formulation | Sep 26, 2026 | Indivior |
| Perseris Kit | US10376590 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
| Perseris Kit | US10406160 | Sustained release small molecule drug formulation | Jun 26, 2026 | Indivior |
| Perseris Kit | US11013809 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
| Perseris Kit | US11110093 | Sustained release small molecule drug formulation | Nov 05, 2026 | Indivior |
| Perseris Kit | US11712475 | Sustained delivery formulations of risperidone compound | Feb 13, 2028 | Indivior |
| Perseris Kit | US9180197 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
| Perseris Kit | US9186413 | Sustained delivery formulations of risperidone compounds | Feb 13, 2028 | Indivior |
| Perseris Kit | US9597402 | Sustained release small molecule drug formulation | Sep 26, 2026 | Indivior |
| Risperdal | US5453425 | Risperidone oral formulation |
Jul 11, 2014
(Expired) | Janssen Pharms |
| Risperdal |
US5453425 (Pediatric) | Risperidone oral formulation |
Jan 11, 2015
(Expired) | Janssen Pharms |
| Risperdal | US5648093 | Pharmaceutical and other dosage forms |
Jul 15, 2014
(Expired) | Janssen Pharms |
| Risperdal |
US5648093 (Pediatric) | Pharmaceutical and other dosage forms |
Jan 15, 2015
(Expired) | Janssen Pharms |
| Risperdal | US6224905 | Biconvex rapidly disintegrating dosage forms |
Jun 10, 2017
(Expired) | Janssen Pharms |
| Risperdal |
US6224905 (Pediatric) | Biconvex rapidly disintegrating dosage forms |
Dec 10, 2017
(Expired) | Janssen Pharms |
| Risperdal | USRE39181 | Aqueous risperidone formulations |
Jul 11, 2014
(Expired) | Janssen Pharms |
| Risperdal |
USRE39181 (Pediatric) | Aqueous risperidone formulations |
Jan 11, 2015
(Expired) | Janssen Pharms |
| Risperdal Consta | US5688801 | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 18, 2014
(Expired) | Janssen Pharms |
| Risperdal Consta |
US5688801 (Pediatric) | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 18, 2015
(Expired) | Janssen Pharms |
| Risperdal Consta | US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta |
US5792477 (Pediatric) | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta | US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta |
US5916598 (Pediatric) | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta | US5965168 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
| Risperdal Consta |
US5965168 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
| Risperdal Consta | US6110921 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6110921 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
| Risperdal Consta | US6194006 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6194006 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
| Risperdal Consta | US6368632 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6368632 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
| Risperdal Consta | US6379703 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6379703 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
| Risperdal Consta | US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6403114 (Pediatric) | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov 02, 2017
(Expired) | Janssen Pharms |
| Risperdal Consta | US6596316 | Preparation of microparticles having a selected release profile |
Dec 30, 2018
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6596316 (Pediatric) | Preparation of microparticles having a selected release profile |
Jun 30, 2019
(Expired) | Janssen Pharms |
| Risperdal Consta | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Janssen Pharms |
| Risperdal Consta |
US6667061 (Pediatric) | Preparation of injectable suspensions having improved injectability |
Nov 25, 2020
(Expired) | Janssen Pharms |
| Risperdal Consta | US7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov 19, 2013
(Expired) | Janssen Pharms |
| Risperdal Consta |
US7547452 (Pediatric) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May 19, 2014
(Expired) | Janssen Pharms |
| Risvan | US10058504 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10085936 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10182982 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10195138 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10335366 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10463607 | Antipsychotic Injectable Depot Composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US10881605 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11007139 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11173110 | Risperidone or paliperidone implant formulation | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11241377 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11752092 | Methods for the preparation of injectable depot compositions | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11752093 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11752094 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Risvan | US11759416 | Antipsychotic injectable depot composition | May 31, 2031 | Labs Farms Rovi Sa |
| Rykindo | US10098882 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
| Rykindo | US10406161 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
| Rykindo | US11110094 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
| Rykindo | US9446135 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
| Rykindo | US9532991 | Risperidone sustained release microsphere composition | Apr 10, 2032 | Shandong Luye |
| Uzedy | US10736965 | Risperidone biodegradable implant | Jan 12, 2025 | Teva |
| Uzedy | US8221778 | Drug-containing implants and methods of use thereof | Nov 12, 2027 | Teva |
| Uzedy | US8741327 | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant | Nov 12, 2027 | Teva |
| Uzedy | US8802127 | Risperidone-containing PLA:PGA implants and methods of use thereof | Jan 12, 2025 | Teva |
| Uzedy | US9023897 | Biodegradable drug delivery compositions | Apr 05, 2033 | Teva |
| Uzedy | US9439905 | Risperidone-containing implants and methods of use thereof | Jan 12, 2025 | Teva |
| Uzedy | US9717799 | Drug-containing implants and methods of use thereof | Jan 12, 2025 | Teva |
| Uzedy | US9895447 | Drug-containing PLA implants and methods of use thereof | Jan 12, 2025 | Teva |
| Uzedy | US9925268 | Drug-containing implants and methods of use thereof | Jan 12, 2025 | Teva |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Risperidone's patents.
Latest Legal Activities on Risperidone's Patents
Given below is the list recent legal activities going on the following patents of Risperidone.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9532991 |
| Surcharge for Late Payment, Large Entity | 17 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10736965 |
| Maintenance Fee Reminder Mailed | 01 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2024 | US9446135 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9439905 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 03 Jan, 2024 | US8221778 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Mar, 2023 | US10406161 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Nov, 2022 | US9023897 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Mar, 2022 | US10098882 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Risperidone Generics
Several generic applications have been filed for Risperidone. The first generic version for Risperidone was by Heritage Pharma Labs Inc Dba Avet Pharmaceuticals Labs Inc and was approved on Jun 30, 2008. And the latest generic version is by Ipca Laboratories Ltd and was approved on Jun 26, 2024.
Given below is the list of companies who have filed for Risperidone generic.
1. TARO
Taro Pharmaceuticals Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Prescription | ORAL | AA | Feb 7, 2011 |
2. AMNEAL
Amneal Pharmaceuticals Llc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
| 4MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
| 3MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
| 2MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
| 0.25MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
| 0.5MG | tablet | Prescription | ORAL | AB | Jun 17, 2009 |
3. PHARM ASSOC
Pharmaceutical Associates Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Pharm Assoc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Jul 29, 2009 |
4. APOTEX INC
Apotex Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Apotex Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
| 3MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
| 0.5MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Sep 15, 2008 |
5. LANNETT CO INC
Lannett Co Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Prescription | ORAL | AA | Dec 3, 2010 |
6. ZYDUS PHARMS USA
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Zydus Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | May 1, 2009 |
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | May 1, 2009 |
7. PRECISION DOSE
Precision Dose Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Precision Dose.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Jun 28, 2010 |
8. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Prescription | ORAL | AA | May 25, 2011 |
9. IPCA LABS LTD
Ipca Laboratories Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Ipca Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
| 3MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
| 2MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
| 1MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
| 0.5MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
| 0.25MG | tablet | Prescription | ORAL | AB | Jun 26, 2024 |
10. RENATA
Renata Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Renata.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
| 3MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
| 0.5MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Dec 29, 2008 |
11. SYNTHON PHARMS
Synthon Pharmaceuticals Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Synthon Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
| 3MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
| 4MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
| 0.25MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
| 1MG | tablet | Discontinued | ORAL | N/A | Oct 22, 2009 |
12. RATIOPHARM
Ratiopharm has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Ratiopharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
| 3MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
| 1MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
| 0.25MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
| 4MG | tablet | Discontinued | ORAL | N/A | Jun 8, 2010 |
13. DASH PHARMS
Dash Pharmaceuticals Llc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Dash Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.25MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Feb 12, 2013 |
| 0.5MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 30, 2011 |
| 1MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 30, 2011 |
| 2MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 30, 2011 |
| 3MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 30, 2011 |
| 4MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 30, 2011 |
14. ZYDUS PHARMS USA INC
Zydus Pharmaceuticals Usa Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Zydus Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
| 4MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
| 0.5MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Oct 16, 2008 |
15. TORRENT PHARMS
Torrent Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Torrent Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
| 4MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
| 3MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 30, 2008 |
16. TRIS PHARMA INC
Tris Pharma Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Tris Pharma Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Prescription | ORAL | AA | Dec 12, 2012 |
17. SUN PHARM INDS INC
Sun Pharmaceutical Industries Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.25MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
| 1MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
| 4MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
| 3MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
| 2MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Mar 10, 2014 |
18. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG/VIAL | injectable | Prescription | INTRAMUSCULAR | AB | Dec 5, 2023 |
| 25MG/VIAL | injectable | Prescription | INTRAMUSCULAR | AB | Dec 5, 2023 |
| 37.5MG/VIAL | injectable | Prescription | INTRAMUSCULAR | AB | Dec 5, 2023 |
| 50MG/VIAL | injectable | Prescription | INTRAMUSCULAR | AB | Dec 5, 2023 |
19. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Jul 29, 2009 |
20. WATSON LABS
Watson Laboratories Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Watson Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
| 1MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
| 2MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
| 3MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
| 4MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
| 0.25MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2008 |
21. SUN PHARM INDS LTD
Sun Pharmaceutical Industries Ltd has filed for 5 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 8, 2013 |
| 4MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 8, 2013 |
| 1MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 8, 2013 |
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 8, 2013 |
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 8, 2013 |
22. HERITAGE PHARMA AVET
Heritage Pharma Labs Inc Dba Avet Pharmaceuticals Labs Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Heritage Pharma Avet.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.25MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
| 1MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
| 2MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
| 3MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
| 4MG | tablet | Discontinued | ORAL | N/A | Oct 16, 2008 |
23. WOCKHARDT
Wockhardt Ltd has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Wockhardt.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Oct 8, 2009 |
24. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 3 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 12, 2012 |
| 1MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 12, 2012 |
| 2MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Mar 12, 2012 |
25. DR REDDYS LABS LTD
Dr Reddys Laboratories Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet, orally disintegrating | Prescription | ORAL | AB | Oct 5, 2009 |
| 4MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 30, 2009 |
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | Feb 24, 2009 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 24, 2008 |
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | Feb 24, 2009 |
| 3MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 30, 2009 |
26. WEST WARD PHARMS
West Ward Pharmaceuticals Corp has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by West Ward Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
| 1MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
| 2MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
| 3MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
| 4MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
| 0.25MG | tablet | Discontinued | ORAL | N/A | May 29, 2009 |
27. SANDOZ
Sandoz Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 22, 2009 |
| 1MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 22, 2009 |
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 22, 2009 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 16, 2009 |
| 4MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 22, 2009 |
| 3MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 22, 2009 |
28. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
| 3MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
| 0.5MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
| 1MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
| 4MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
| 0.25MG | tablet | Prescription | ORAL | AB | Aug 24, 2011 |
29. CELLTRION
Celltrion Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Celltrion.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
| 3MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
| 4MG | tablet | Prescription | ORAL | AB | Oct 9, 2008 |
30. JUBILANT CADISTA
Jubilant Cadista Pharmaceuticals Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Jubilant Cadista.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
| 0.25MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
| 1MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
| 2MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
| 3MG | tablet | Discontinued | ORAL | N/A | Mar 23, 2009 |
31. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
| 4MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
| 3MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
| 2MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
| 1MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
| 0.25MG | tablet | Prescription | ORAL | AB | Nov 29, 2011 |
32. RISING
Rising Pharma Holdings Inc has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
| 4MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
| 3MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
| 2MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
| 1MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
| 0.25MG | tablet | Prescription | ORAL | AB | Oct 8, 2008 |
33. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Ani Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Jan 30, 2009 |
34. CHARTWELL MOLECULAR
Chartwell Molecular Holdings Llc has filed for 7 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Chartwell Molecular.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 4MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 3MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 2MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 0.5MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 0.25MG | tablet | Prescription | ORAL | AB | May 18, 2011 |
| 1MG/ML | solution | Prescription | ORAL | AA | Jan 12, 2015 |
35. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Prescription | ORAL | AA | Sep 4, 2009 |
36. ENDO OPERATIONS
Endo Operations Ltd has filed for 6 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.25MG | tablet, orally disintegrating | Prescription | ORAL | N/A | Apr 30, 2009 |
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 30, 2009 |
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 30, 2009 |
| 3MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 30, 2009 |
| 4MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 30, 2009 |
| 1MG | tablet, orally disintegrating | Prescription | ORAL | AB | Oct 26, 2009 |
37. APOZEAL PHARMS
Apozeal Pharmaceuticals Inc has filed for 1 generic for Risperidone. Given below are the details of the strengths of this generic introduced by Apozeal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | solution | Discontinued | ORAL | N/A | Jul 29, 2009 |
38. JUBILANT GENERICS
Jubilant Generics Ltd has filed for 5 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Jubilant Generics.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 4, 2011 |
| 2MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 4, 2011 |
| 4MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 4, 2011 |
| 1MG
(reference standard) | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 4, 2011 |
| 3MG | tablet, orally disintegrating | Prescription | ORAL | AB | Nov 4, 2011 |
39. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 5 different strengths of generic version for Risperidone. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Apr 19, 2011 |
| 0.5MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Apr 19, 2011 |
| 1MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Apr 19, 2011 |
| 3MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Apr 19, 2011 |
| 2MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Apr 19, 2011 |